trial

Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia

NCTId NCT02907437
as of 2026-07-01
at a glance
Phase 3 · Unknown
Enrollment 40 (estimated)
Primary completion 2017-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-01
Primary completion
2017-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Sponsors

Investigators

1
Rafael Octavio Stryjer, MDPrincipal Investigator

Sites

1 total
Beer Yaakov, Israel

Linked catalysts

1

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE3
Primary Completion Date
2017-02
Status
UNKNOWN
relationships
The graph out of here